CALCR calcitonin receptor
ENSG00000004948 · protein coding · Open Targets profile
G protein-coupled receptor activated by ligand peptides amylin (IAPP), calcitonin (CT/CALCA) and calcitonin gene-related peptide type 1 (CGRP1/CALCA) (PubMed:35324283, PubMed:38603770). CALCR interacts with receptor-activity-modifying proteins RAMP1, 2 and 3 to form receptor complexes AMYR1, 2 and 3, respectively (PubMed:35324283, PubMed:38603770). IAPP, CT and CGRP1 activate CALCR and AMYRs with distinct modes of receptor activation resulting in specific phenotypes (PubMed:35324283, PubMed:38603770). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide- binding proteins (G proteins) and modulates the activity of downstream effectors. Activates cAMP-dependent pathway (PubMed:35324283, PubMed:7476993). {ECO:0000269|PubMed:35324283, ECO:0000269|PubMed:38603770, ECO:0000269|PubMed:7476993}.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Structure with Ligand, High-Quality Ligand, Druggable Family
- Antibody
- UniProt loc high conf, GO CC high conf, UniProt SigP or TMHMM
- PROTAC
- Small Molecule Binder
- Other modalities
- Approved Drug
gnomAD loss of function constraint: o/e 0.7899699807167053 (upper bound 1.0074000358581543). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 52 registry trials, updated in the last three years, of the most advanced drugs against CALCR (pramlintide, calcitonin human, SMC021, davalintide), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Ahmad HaidarMcGill University Health Centre/Research Institute of the McGill University Health Centre · 1 of 1 trials Phase 2+
- Andrea ValasquezWorldwide Clinical Trials · 1 of 1 trials Phase 2+
- Arjen DondorpMahidol Oxford Tropical Medicine Research Unit · 1 of 1 trials Phase 2+
- Brett CristUniversity of Missouri-Columbia · 1 of 1 trials Phase 2+
- Brooks CashThe University of Texas Health Sciences Center at Houston · 1 of 1 trials Phase 2+
- Claus Bogh JuhlHead of endocrinology dept. · 1 of 1 trials Phase 2+
- Francoise BodereNantes University Hospital · 1 of 1 trials Phase 2+
- George AtieeWorldwide Clinical Trials · 1 of 1 trials Phase 2+
- Konrad P WeberUniversity Hospital Zurich, Department of Neurology · 1 of 1 trials Phase 2+
- Laurent LegaultMontreal's Children's Hospital Division of Endocrinology · 1 of 1 trials Phase 2+
- Melissa-Rosina PasquaMcGill University Health Centre/Research Institute of the McGill University Health Centre · 1 of 1 trials Phase 2+
- Michael TsoukasMcGill University Health Centre/Research Institute of the McGill University Health Centre · 1 of 1 trials Phase 2+
- Michael VallisDalhousie University Psychologist · 1 of 1 trials Phase 2+
- mohamed G. Zeinhomneurology department kafr el-sheikh university · 1 of 1 trials Phase 2+
- Natasha GarfieldRoyal Victoria Hospital Division of Endocrinology · 1 of 1 trials Phase 2+
Registry trials of pramlintide, calcitonin human, SMC021, davalintide updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 46 of 48 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 4 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
23 trials of drugs against CALCR were stopped early; 4 give no reason
Terminated, withdrawn and suspended interventional trials of pramlintide, calcitonin human, SMC021, davalintide, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 23 most recent of 23.
- withdrawn · 2026-04-17 · Esbjerg Hospital - University Hospital of Southern Denmark · Pramlintide Acetate 1 MG/ML“suspended by the danish medical agency”
- terminated · 2025-11-17 · Centre Hospitalier Departemental Vendee · matched by the registry's drug synonymsNo reason given
- terminated · 2024-05-29 · H. Lundbeck A/S · matched by the registry's drug synonyms“The study was terminated due to enrolment challenges.”
- terminated · 2024-04-02 · University of Maryland, Baltimore · matched by the registry's drug synonyms“Low enrollment rate”
- terminated · 2024-03-22 · University of Maryland, Baltimore · matched by the registry's drug synonyms“Low enrollment rate”
- terminated · 2023-09-29 · Diamond Headache Clinic · matched by the registry's drug synonyms“Stopped from financial sponsor due to inability to enroll participants.”
- withdrawn · 2023-06-28 · H. Lee Moffitt Cancer Center and Research Institute · Pramlintide“Poor accrual”
- terminated · 2022-03-28 · University of Virginia · matched by the registry's drug synonyms“Clinical staffing issues and COVID-19 pandemic”
- withdrawn · 2021-07-22 · University of Maryland, Baltimore · Pramlintide acetate“Sponsor could not fund.”
- terminated · 2021-07-14 · H. Lee Moffitt Cancer Center and Research Institute · matched by the registry's drug synonyms“Lack of efficacy”
- terminated · 2020-10-20 · Texas Diabetes & Endocrinology, P.A. · matched by the registry's drug synonyms“Lack of patient population”
- terminated · 2019-04-24 · Nordic Bioscience A/S · matched by the registry's drug synonyms“Male subjects were terminated due to an imbalance in prostate cancer events”
- withdrawn · 2019-01-08 · University of Texas Southwestern Medical Center · PramlintideNo reason given
- withdrawn · 2018-07-26 · University of Colorado, Denver · PramlintideNo reason given
- terminated · 2018-07-23 · Brahms AG · matched by the registry's drug synonyms“At 75% patient completion overall mortality was much lower than expected and without significant difference at day 90. No chance to reach the primary endpoint.”
- withdrawn · 2015-12-04 · Unidad de Investigacion en Enfermedades Cronico-Degenerativas · matched by the registry's drug synonyms“Study drug was not longer available in our country.”
- withdrawn · 2015-09-02 · Rijnstate Hospital · matched by the registry's drug synonyms“No MEC approval”
- terminated · 2015-04-15 · AstraZeneca · Pramlintide+Metreleptin“Results from previous study DFA102 demonstrated neutralizing activity to metreleptin in invitro assay in 2 participants.”
- terminated · 2014-05-01 · University of Virginia · Closed loop with pramlintide, Open loop with pramlintide“Modified study; created new study as a result of these modifications”
- terminated · 2010-12-06 · Brahms France · matched by the registry's drug synonyms“65 patients were included after 2 years instead of 140”
- terminated · 2010-07-07 · Assistance Publique - Hôpitaux de Paris · matched by the registry's drug synonyms“Insuffisent recruitment”
- terminated · 2008-06-04 · Université de Montréal · matched by the registry's drug synonyms“Medication expired”
- terminated · 2006-09-14 · Université Catholique de Louvain · matched by the registry's drug synonymsNo reason given
Paediatric incentives and obligations for CALCR's drugs
For pramlintide, calcitonin human, SMC021, davalintide: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · CALCR is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: no · No EMA paediatric investigation plan decision names pramlintide, calcitonin human, smc021, davalintideRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: no · No EU orphan designation names pramlintide, calcitonin human, smc021, davalintideRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: no · EMA lists no centrally authorised medicine of pramlintide, calcitonin human, smc021, davalintideRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of pramlintide, calcitonin human, smc021, davalintideRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: yes · 22 interventional studies of pramlintide, calcitonin human, smc021, davalintide include patients under 18; 1 is recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 7 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.